Study summary
AMX0035 showed no benefit in PSP, and the trial was stopped
What was tested
AMX0035 (sodium phenylbutyrate and taurursodiol), a combination pill aimed at protecting nerve cells, against placebo, in a phase 2b/3 trial in PSP.
What they found
- An interim analysis showed no difference from placebo on primary or secondary outcomes.
- Amylyx stopped the trial and its extension; safety was not the reason.
What it means
One of several setbacks that have pushed the field toward drugs that target tau directly.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.